Cardiologist and Patient Care author Payal Kohli, MD offers snap shots of 6 influential studies that will affect the future of AF diagnosis and treatment.
For more information: Cannon CP, Bhatt DL, Oldgren J, et al for the RE-DUAL PCI Steering Committee and Investigators. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. NEJM. Published online August 27, 2017.
For more information: BjÃ¶rkenheim A, Brandes A, Magnuson A, et al. Assessment of atrial fibrillation-specific symptoms before and 2 years after atrial fibrillation ablation. Do patients and physicians differe in their perceptions of symptom relief? JACC: EP. June 2017, 405.
For more information: Krivoshei L, Weber S, Burkard T, et al. Smart detection of atrial fibrillation. Europace. 2017;19:753-757 and Halcox JPJ, Wareham K, Cardew A, et al. Assessment of remote heart rhythm sampling using the AliveCor heart monitor to screen for atrial fibrillation: The REHEARSE-AF study. Circulation 2017.CIRCULATIONAHA.117.030583
2017 was a roller-coaster year in cardiology research with trials such as the CAD sham-controlled ORBITA trial turning our beliefs about revascularization upside down and the new ACC/AHA hypertension guidelines generating controversy from the community given the far-reaching implications suggested.Â As a sampling, here is Part 1 of my top 6 study picks in the world of atrial fibrillation that I reviewed on Patient Care during 2017 and why I think they are important.For Part II, please click here.Â